GYRE
NASDAQ
US
Gyre Therapeutics, Inc. - Common Stock
$7.12
▼ $-0.11
(-1.52%)
Vol 64K
8
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$641.7M
P/E
96.5
ROE
8.2%
Margin
6.2%
D/E
0.00
Beta
2.49
52W
$6–$14
Wall Street Consensus
9 analysts · Apr 20263
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
BBOT
BridgeBio Oncology Therapeutics Inc
P/E 212.3
$1.0B
REPL
Replimune Group Inc
$762.5M
DSGN
Design Therapeutics Inc
$534.3M
PURR
Hyperliquid Strategies Inc
ALLO
Allogene Therapeutics Inc
$307.9M
PRME
Prime Medicine Inc
$626.4M
OCGN
Ocugen Inc
$421.6M
MDXG
MiMedx Group Inc
P/E 24.6
$1.0B
IRWD
Ironwood Pharmaceuticals Inc
P/E 19.2
$548.2M
Earnings
Beat rate: 25.0%
Next Report
May 07, 2026
EPS Estimate: $-0.07
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.07 | — | — |
| Dec 2025 | $0.06 | $0.05 | $-0.01 |
| Sep 2025 | $0.03 | $0.08 | +$0.05 |
| Jun 2025 | $0.03 | $0.02 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $27.9M | $22.1M | $26.8M | $30.6M | $37.2M |
| Net Income | — | -$99K | $2.7M | $442K | $3.6M | -$1.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 5.8% | 5.8% | 5.8% | 5.8% | 8.2% | 8.2% |
| P/E (TTM) | 155.47 | 166.17 | 167.59 | 169.01 | 110.80 | 96.48 |
| Net Margin | 1.6% | 4.1% | 4.1% | 4.1% | 6.2% | 6.2% |
| Gross Margin | 95.7% | 95.9% | 95.9% | 95.9% | 95.5% | 95.5% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.40 | 5.40 | 5.40 | 5.40 | 6.19 | 6.19 |
Key Ratios
ROA (TTM)
4.7%
P/S (TTM)
5.98
P/B
17.9
EPS (TTM)
$0.06
CF/Share
$-18.23
Rev Growth 3Y
+143.3%
52W High
$14.42
52W Low
$6.11
$6.11
52-Week Range
$14.42
Financial Health
Free Cash Flow
-$5.8M
Net Debt
-$36.1M
Cash
$37.1M
Total Debt
$939K
As of Dec 31, 2025
How does GYRE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GYRE valuation vs Biotechnology peers
P/E ratio
96.5
▲
414%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
6.0
▼
53%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
17.9
▲
626%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GYRE profitability vs Biotechnology peers
ROE
8.2%
▲
112%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
6.2%
▲
102%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
95.5%
▲
21%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
4.7%
▲
110%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
GYRE financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
6.2
▲
40%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.5
▲
157%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
GYRE fundamentals radar
GYRE
Peer median
Industry
GYRE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GYRE vs peers: key metrics
Top Holders
Top 5: 2.8%Vanguard Group Inc
1.24%
$8.1M
Blackrock Inc.
0.74%
$4.9M
Geode Capital Management, L…
0.44%
$2.9M
State Street Corporation
0.21%
$1.4M
Charles Schwab Investment M…
0.17%
$1.1M
As of Dec 31, 2025
Dividends
$921.23
/ year
Jan 13, 2023
$3.6000
Sep 21, 2022
$21.4500
Aug 20, 2015
$896.1750
Latest News
No related news yet